DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong-Analyst
DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong-Analyst
DexCom Inc (NASDAQ:DXCM) reported second-quarter sales of more than $1 billion. That's up 15% year-over-year on a reported basis and 16% on an organic basis.
DexCom Inc（NASDAQ: DXCM）報告第二季度銷售額超過10億美元。按照報告數據計算，同比增長15％，按照有機數據計算，同比增長16％。
The glucose monitoring device maker reported a second-quarter adjusted EPS of 43 cents. That's up from 34 cents a year ago, beating the consensus of 39 cents.
該葡萄糖監測設備製造商報告第二季度調整後的每股收益爲43美分。同比增長從34美分增加，超過39美分的共識。
The company expects 2024 sales of $4.00 billion—$4.05 billion (11 – 13% organic growth), down from prior guidance of $4.20 billion—$4.35 billion versus a consensus of $4.33 billion.
該公司預計2024年銷售額爲40億—405億美元（有機增長11-13％），低於之前的指導範圍42億—43.5億美元，而共識爲43.3億美元。
Related: FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's.
相關：DexCom的Stelo獲得FDA批准，開啓連續葡萄糖監測進入大衆市場，分析師預計與Abbott競爭定價有利。
William Blair writes that "the bigger surprise was that management decreased guidance by $200million-$300 million for the full year. This change we believe has led investors to question the longer-term growth profile for DexCom, and ultimately led to the stock being indicated down."
William Blair寫道：“更大的驚喜是管理層將全年指導下調了2000萬到3000萬美元。我們認爲這種變化導致投資者質疑DexCom的長期增長前景，最終導致股票被指示下跌。”
"We remain believers in the story given our view of the market outlook and DexCom's strong product portfolio and ecosystem. We believe the reasons for the miss and guide down are (painfully) self-inflicted, though ultimately, should prove transient and manageable. As a result, we maintain our Outperform rating," the analyst adds.
“鑑於我們對市場前景和DexCom強大的產品組合和生態系統的看法，我們仍然相信這個故事。我們認爲未能達成目標和指導是（痛苦地）自引發的，但最終應該能夠過渡並得到管理。因此，我們維持我們的跑贏市場評級，”分析師補充道。
William Blair anticipates domestic continuous glucose monitoring market growth in the high teens through 2027. The firm also expects potential for mid-20% growth in a bull case.
William Blair預計，到2027年，國內連續血糖監測市場的增長率將達到高雙位數。該公司還期望在看漲案例中有可能實現25％的增長。
The analyst says DexCom can expand the market through increased coverage and reclaim recent market share losses by improving its pharmacy channel expansion and re-engaging the DME channel.
分析師表示，DexCom可以通過增加覆蓋範圍，並通過改善其藥房渠道擴張和重新參與DME渠道來重新奪回市場份額，從而擴大市場。
These short-term issues are expected to be temporary. William Blair foresees significant growth potential in intensive insulin users.
這些短期問題預計將是暫時的。William Blair預見強化胰島素用戶的顯着增長潛力。
Price Action: DXCM stock is down 40% at $64.78 at last check Friday.
股票價格行動：DXCm股票價格上週五最後一次檢查下跌40％至64.78美元。
- Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events.
- 渤健公司/艾伯細胞的阿爾茨海默病藥物Leqembi在歐洲藥品監管機構諮詢委員會中未經過，稱有嚴重的副作用。